Recommendations from the AML molecular MRD expert advisory board-Reference-Cited by-同舟云学术

Recommendations from the AML molecular MRD expert advisory board

Published:2024-05-23 Issue:7 Volume:38 Page:1638-1641
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Scott Stuart^ORCID,Devonshire Alison^ORCID,Dillon Richard^ORCID,Thiede Christian,Cross Nicholas C. P.^ORCID,White Helen E.,Lo Cascio Leandro,Mokretar Katya,Potter Nicola^ORCID,Hourigan Christopher S.,Radich Jerald^ORCID,Corner Adam,Laloux Véronique,Halliday Gemma,Dilks Daniel,Morrison Tom,Gilmour Katelyn,Cartwright Ashley,Whitby Liam

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41375-024-02275-x.pdf

Reference15 articles.

1. Bhansali RS, Pratz KW, Lai C. Recent advances in targeted therapies in acute myeloid leukemia. J Hematol Oncol. 2023;16:1–27.

2. United States Food and Drug Administration. Hematologic Malignancies: Regulatory Considerations for Use of Minimal Residual Disease in Development of Drug and Biological Products for Treatment Guidance for Industry. 2020 Jan. United States Food and Drug Administration. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/hematologic-malignancies-regulatory-considerations-use-minimal-residual-disease-development-drug-and (accessed 4 Aug 2023).

3. Schuurhuis GJ, Heuser M, Freeman S, Béné M-C, Buccisano F, Cloos J, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018;131:1275–91.

4. UK NEQAS LI Home Page - Measurable Residual Disease for AML by Molecular Methods (Pilot - Not Accredited). https://www.ukneqasli.co.uk/eqa-pt-programmes/molecular-haemato-oncology-programmes/measurable-residual-disease-for-aml-by-molecular-methods-pilot-not-accredited/ (accessed 4 Aug 2023).

5. Scott S, Cartwright A, Francis S, Whitby L, Sanzone AP, Mulder A, et al. Assessment of droplet digital polymerase chain reaction for measuring BCR-ABL1 in chronic myeloid leukaemia in an international interlaboratory study. Br J Haematol. 2021;194:53–60.